Synmosa Biopharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Synmosa Biopharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	36.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Apr 04

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Mar 08

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 31

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 09

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Synmosa Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TPEX:4114 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	5,140	595	251	512	N/A
9/30/2023	5,059	585	204	470	N/A
6/30/2023	4,931	562	358	614	N/A
3/31/2023	4,677	800	337	570	N/A
12/31/2022	4,386	799	446	630	N/A
9/30/2022	4,048	735	426	585	N/A
6/30/2022	3,721	693	466	594	N/A
3/31/2022	3,441	368	394	536	N/A
12/31/2021	3,235	304	313	455	N/A
9/30/2021	3,141	288	403	520	N/A
6/30/2021	3,105	293	218	350	N/A
3/31/2021	3,012	634	244	379	N/A
12/31/2020	3,038	638	77	254	N/A
9/30/2020	2,931	582	-52	140	N/A
6/30/2020	2,861	519	-136	67	N/A
3/31/2020	2,849	95	-316	-104	N/A
12/31/2019	2,680	47	-247	-45	N/A
9/30/2019	2,579	40	-321	-54	N/A
6/30/2019	2,486	61	-292	-11	N/A
3/31/2019	2,384	73	-249	128	N/A
12/31/2018	2,363	431	-350	16	N/A
9/30/2018	2,249	432	-276	-106	N/A
6/30/2018	2,119	409	-141	57	N/A
3/31/2018	2,017	379	-194	9	N/A
12/31/2017	1,861	5	-235	-5	N/A
9/30/2017	1,795	-34	N/A	76	N/A
6/30/2017	1,772	-38	N/A	20	N/A
3/31/2017	1,821	-6	N/A	144	N/A
12/31/2016	1,865	165	N/A	236	N/A
9/30/2016	1,894	173	N/A	279	N/A
6/30/2016	1,926	180	N/A	186	N/A
3/31/2016	1,856	180	N/A	82	N/A
12/31/2015	1,776	32	N/A	24	N/A
9/30/2015	1,706	58	N/A	-30	N/A
6/30/2015	1,644	75	N/A	-43	N/A
3/31/2015	1,562	97	N/A	-118	N/A
12/31/2014	1,476	110	N/A	-11	N/A
9/30/2014	1,423	122	N/A	21	N/A
6/30/2014	1,329	107	N/A	28	N/A
3/31/2014	1,275	91	N/A	76	N/A
12/31/2013	1,249	63	N/A	30	N/A
9/30/2013	1,207	50	N/A	78	N/A
6/30/2013	1,177	53	N/A	84	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4114's forecast earnings growth is above the savings rate (1%).

Earnings vs Market: Insufficient data to determine if 4114's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 4114's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 4114's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 4114's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4114's Return on Equity is forecast to be high in 3 years time

Synmosa Biopharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Synmosa Biopharma Corporation Provides Earnings Guidance for the Year 2022

Price target raised to NT$28.00

Recent updates

Full year 2023 earnings released: EPS: NT$1.61 (vs NT$2.25 in FY 2022)

Synmosa Biopharma Corporation, Annual General Meeting, May 30, 2024

Synmosa Biopharma Corporation Announces Changes in Fifth Session of the Remuneration Committee

Third quarter 2023 earnings released: EPS: NT$0.35 (vs NT$0.32 in 3Q 2022)

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: NT$0.46 (vs NT$1.13 in 2Q 2022)

Upcoming dividend of NT$0.56 per share at 1.4% yield

Synmosa Biopharma Corporation Announces Cash Dividend, Payable on September 15, 2023

Synmosa Biopharma Corporation Appoints Tu, San-Chien as Additional Independent Director

New minor risk - Shareholder dilution

Synmosa Biopharma Corporation announced that it expects to receive TWD 950 million in funding

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2023

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2023

Investor sentiment improved over the past week

Synmosa Biopharma Corporation Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: NT$0.35 (vs NT$0.21 in 3Q 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.35 (vs NT$0.21 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$1.24 (vs NT$0.23 in 2Q 2021)

Upcoming dividend of NT$0.51 per share

Investor sentiment improved over the past week

Synmosa Biopharma Corporation Announces Changes to the Compensation Committee

First quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.20 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$1.02 (vs NT$2.20 in FY 2020)

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2022

Third quarter 2021 earnings released: EPS NT$0.24 (vs NT$0.25 in 3Q 2020)

Upcoming dividend of NT$0.30 per share

Second quarter 2021 earnings released: EPS NT$0.29 (vs NT$1.66 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.23 (vs NT$0.26 in 1Q 2020)

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Synmosa Biopharma Corporation Approves Cash Dividends

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2021

Full year 2020 earnings released: EPS NT$2.46 (vs NT$0.20 in FY 2019)

Revenue beats expectations

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

New 90-day low: NT$24.05

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Third quarter 2020 earnings released: EPS NT$0.28

New 90-day high - NT$27.60

Price target raised to NT$28.00

New 90-day high - NT$26.95

First half earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies